2月26日，Mesoblast公司公布了Ryoncil的定价。单次静脉输注19.4万美元（2×106MSC/kg）， 完整疗程（需注射8次）费用高达155.2万美元（折合人民币超1100万元），且与体重无关 ...

2024年12月18日，Ryoncil®凭借其创新性和临床有效性，成为了FDA批准的首个MSC（干细胞）疗法。终于在2025年2月26日，Mesoblast Limited（纳斯达克股票代码：MESO；ASX：MSB）公告了其革命性产品Ryoncil®（remestemcel-L）的定价策略。

Ryoncil is an allogeneic mesenchymal stromal cell (MSC) therapy indicated for the treatment of acute graft-versus-host ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013.

Manufacturing: As a result of FDA approval of RYONCIL in December 2024, the US$23.0 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now ...

Each year, approximately 375 pediatric patients in the U.S. are diagnosed with SR-aGvHD. The cost of treating a child who dies of SR-aGvHD within 12 months of transplant is approximately US$2.5 ...

Mesoblast has set a price for its recently-approved flagship drug, which will go to market over the next few weeks. The post Mesoblast share price rips 12% on financial and operational updates ...